Actively Recruiting
Reduced-Dose Radiation Treatment for HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Led by University of California, Irvine · Updated on 2026-05-05
111
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying patients with human papillomavirus HPV positive oropharyngeal squamous cell carcinoma to understand the effects of lowering the radiation dose in treatment. This observational registry study focuses on patients with clinical stage I, II, or III disease, excluding those with distant metastases. The goal is to evaluate how reducing radiation affects disease progression over a two-year period. Participants receive intensity-modulated radiation therapy IMRT given in 30 daily treatments of 2 Gy each, totaling 60 Gy, delivered six times per week starting on Day 1. High risk patients may also receive two cycles of chemotherapy with carboplatin and paclitaxel before radiation. The study monitors patients without randomization or comparison groups. During the study, participants will undergo assessments such as physical exams, weight checks, and PETCT scans within six weeks before starting treatment. Researchers will monitor progression-free survival, overall survival, and local-regional control for up to two years from registration. This helps understand how well the reduced radiation dose controls the cancer and affects patient outcomes over time.
CONDITIONS
Brief Title
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
U
University of California Irvine Medical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
